Na-AIP-1 secreted by human hookworms suppresses collagen-induced arthritis

Proteins from helminths have been posed as new immunomodulatory agents with exciting potential in the treatment of immune-mediated diseases including rheumatoid arthritis (RA). In this study we assess the effects of a helminthic excretory/secretory (ES) protein Na-AIP-1 as monotherapy and in combination with methotrexate (MTX) in the well-described collagen-induced arthritis (CIA) model of RA. CIA was induced in DBA/1 J mice which were treated after the onset of arthritis with Na-AIP-1 monotherapy, MTX or Na-AIP-1 + MTX. The clinical scores for weight, arthritis and paw width were recorded along with joint histology as outcome measures. For the clinical parameters of weight, paw score and paw width, none of the Na-AIP-1 monotherapy, MTX therapy or Na-AIP-1 + MTX combination therapy groups displayed any significant difference when compared to the arthritis control. However, a significant reduction in histological score was identified after both monotherapy (Na-AIP-1: 0.83 +/- 0.24 vs Arthritis control: 5.58 +/- 1.49, p = 0.0277) and combination therapy (Na-AIP-1 + MTX: 0.55 +/- 0.28 vs Arthritis control: 5.58 +/- 1.49, p = 0.0233) when compared to arthritis control. Furthermore, Na-AIP-1 as both monotherapy (Na-AIP-1: 0.83 +/- 0.24 vs MTX: 5.73 +/- 1.82 p = 0.0261) and combination therapy (Na-AIP-1 + MTX: 0.55 +/- 0.28 vs MTX: 5.73 +/- 1.82, p = 0.0221) also significantly reduced histological score when compared to MTX monotherapy. Na-AIP-1 significantly reduced joint pathology in CIA. The hookworm protein Na-AIP-1 seems to be effective in the treatment of RA as monotherapy and when dosed together with MTX, constituting a potential new candidate for drug development. Research should focus on elucidating the mechanism of Na-AIP-1 action as a means to identify novel targets for therapeutics and to further our current understanding of immunobiology in RA.

Automated summary

This study assessed the effects of a helminthic protein Na-AIP-1 as monotherapy and in combination with MTX in the treatment of rheumatoid arthritis (RA). The results showed that Na-AIP-1, either as monotherapy or in combination with MTX, significantly reduced joint pathology in a mouse model of RA. This suggests that Na-AIP-1 could be a potential new candidate for drug development in the treatment of RA.